NEW YORK, Feb. 5, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on AERI, AZN, CPHI, and GSK which can be accessed for free by signing up to www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Aerie Pharmaceuticals Inc. (NASDAQ: AERI), AstraZeneca
Irvine, California-based Aerie Pharmaceuticals Inc.'s shares recorded a trading volume of 384,316 shares last Friday, which was above their three months average volume of 363,030 shares. The stock finished the trading session 0.17% lower at $57.05. The Company's shares have gained 29.59% over the past year. The stock is trading above its 200-day moving average by 3.80%. Furthermore, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have a Relative Strength Index (RSI) of 45.80.
On January 26th, 2018, research firm Seaport Global Securities initiated a 'Buy' rating on the Company's stock, with a target price of $78 per share.
On February 01st, 2018, Aerie Pharma announced the appointment of Tad Heitmann as Head of Communications, reporting to Judith Robertson, Chief Commercial Officer. Mr. Heitmann will head the Company's corporate, commercial, and internal communications activities. Get the full research report on AERI for free by clicking below at: www.wallstequities.com/registration/?symbol=AERI
On Friday, Cambridge, the UK headquartered AstraZeneca PLC's stock ended the session 2.16% higher at $35.90. A total volume of 7.47 million shares was traded, which was above their three months average volume of 3.13 million shares. The Company's shares have gained 1.27% in the last month, 3.88% over the previous three months, and 30.26% over the past year. The stock is trading 4.68% above its 50-day moving average and 8.45% above its 200-day moving average. Moreover, shares of AstraZeneca, which develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 58.81.
On January 12th, 2018, AstraZeneca and Merck (Merck: known as MSD outside the US and Canada) announced that the US Food and Drug Administration has approved LYNPARZA® (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative metastatic breast cancer, who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
On January 18th, 2018, research firm Leerink Partners reiterated its 'Market Perform' rating on the Company's stock with an increase of the target price from $33 a share to $36 a share. The free technical report on AZN can be accessed at: www.wallstequities.com/registration/?symbol=AZN
China Pharma Holdings
Haikou, China headquartered China Pharma Holdings Inc.'s stock ended the day 4.41% lower at $0.32 with a total trading volume of 272,362 shares. The Company's shares have surged 89.06% in the last month, 97.93% over the previous three months, and 35.30% over the past year. The stock is trading 21.23% and 50.25% above its 50-day and 200-day moving averages, respectively. Additionally, shares of China Pharma, which develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in China, have an RSI of 48.07. Sign up for free on Wall St. Equities and claim the latest report on CPHI at: www.wallstequities.com/registration/?symbol=CPHI
Shares in Brentford, the UK headquartered GlaxoSmithKline PLC recorded a trading volume of 3.33 million shares. The stock ended Friday's session 1.30% lower at $37.10. The Company's shares have gained 0.84% in the last month and 2.49% over the previous three months. The stock is trading above its 50-day moving average by 2.05%. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 46.80.
On January 12th, 2018, GlaxoSmithKline announced that it has received approval from the US Food and Drug Administration's Center for Biologics Evaluation and Research expanding the indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) to include use in persons six months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses in persons three years of age and older. See the free research coverage on GSK at: www.wallstequities.com/registration/?symbol=GSK
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----aerie-pharma-astrazeneca-china-pharma-and-glaxosmithkline-300593256.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All